Abstract：Objective: To explore the relationship between SOX17 gene methylation in plasma circulating DNA and the disease condition and prognosis of patients with papillary thyroid carcinoma (PTC). Methods: Thyroid cancer tissue and preoperative blood samples were collected from 152 PTC patients who underwent surgical resection between June 2022 and December 2023. Methylation-specific PCR (MSP) was used to detect SOX17 promoter methylation in PTC tissues and plasma circulating DNA. Results: MSP results showed that 71 out of 152 PTC tissue samples (46.7%) and 76 plasma circulating DNA samples (50.0%) exhibited SOX17 methylation. Spearman correlation analysis indicated a significant correlation between SOX17 methylation in plasma circulating DNA and PTC tissues (r=0.382, P<0.001). SOX17 methylation in PTC tissue and plasma circulating DNA was significantly associated with tumor stages Ⅱ~Ⅲ, tumor size ≥2cm, and lymph node metastasis (LNM) (P<0.05). Furthermore, SOX17 methylation in plasma circulating DNA was significantly related to the occurrence of extrathyroidal extension (ETE) (P<0.05). SOX17 methylation in plasma circulating DNA was identified as an independent factor influencing LNM and ETE in PTC patients (OR=9.564, 2.744; 95% CI=3.875~23.602, 1.109~6.792, P<0.05). The predictive ability of SOX17 methylation in plasma circulating DNA for LNM and ETE was relatively high, with an area under the curve (AUC) of 0.731 and 0.630 (sensitivity 74.0%, 65.6%; specificity 72.2%, 60.4%). In contrast, the predictive ability of SOX17 methylation in PTC tissues for LNM and ETE was lower, with an AUC of 0.604 and 0.562 (sensitivity 57.5%, 54.1%; specificity 63.3%, 58.2%). Conclusion: SOX17 promoter methylation in tumor tissue and plasma DNA exhibits high consistency during the occurrence and progression of PTC. Moreover, SOX17 promoter methylation in plasma DNA has a higher predictive value for LNM and ETE.
晁祥嵩, 孙佳斌, 赵长海. 甲状腺癌血浆循环DNA中SOX17基因甲基化与患者病情及预后的关系[J]. 河北医学, 2024, 30(10): 1695-1699.
CHAO Xiangsong, SUN Jiabin, HOU Yinglong. Methylation of SOX17 Gene in Plasma Circulating DNA and Its Correlation with Disease Status and Prognosis in Patients with Papillary Thyroid Carcinoma. HeBei Med, 2024, 30(10): 1695-1699.
[1] Amanullah M,Pan M,Lu K,et al.Tumor-infiltrating immune cell landscapes in the lymph node metastasis of papillary thyroid cancer[J].Curr Oncol,2023,30(3): 2625-2641. [2] Song B,Lin Z,Feng C,et al.Global research landscape and trends of papillary thyroid cancer therapy: a bibliometric analysis[J].Front Endocrinol,2023(14): 1252389. [3] Hu H,Ho D H H,Tan D S,et al.Evaluation of the determinants for improved pluripotency induction and maintenance by engineered SOX17[J].Nucleic Acids Res,2023,51(17): 8934-8956. [4] Goto N,Westcott P M K,Goto S,et al.SOX17 enables immune evasion of early colorectal adenomas and cancers[J].Nature,2024,627(8004): 636-645. [5] Connal S,Cameron J M,Sala A,et al.Liquid biopsies: the future of cancer early detection[J].Transl Med,2023,21(1): 118. [6] Lianidou E.Detection and relevance of epigenetic markers on ctDNA: recent advances and future outlook[J].Mol Oncol,2021,15(6): 1683-1700. [7] Vitale I,Shema E,Loi S,et al.Intratumoral heterogeneity in cancer progression and response to immunotherapy[J].Nat Med,2021,27(2): 212-224. [8] Ming X,Duppee J L,Gallo V,et al.SOX17 promotes oligodendrocyte regeneration by dual modulation of hedgehog and Wnt signaling[J].Iscience,2020,23(10): 101592. [9] Zhang W,Ruan X,Li Y,et al.KDM1A promotes thyroid cancer progression and maintains stemness through the Wnt/β-catenin signaling pathway[J].Theranostics,2022,12(4): 1500. [10] Sheikholeslami S,Zarif-yeganeh M,Farashi S,et al.Promoter methylation of tumor suppressors in thyroid carcinoma: a systematic review[J].Iran Public Health,2021,50(12): 2461-2472.
2024, Vol. 30 
冀公网安备13080202000677号